Blood Glucose Monitoring News
-
CD Formulation Introduces Comprehensive Range of Microsphere and Microneedle Solutions for Pharma and Biotech Applications
CD Formulation, a leading provider of innovative pharmaceutical formulation services, has recently launched a comprehensive range of microsphere and microneedle solutions for pharmaceutical and biotech applications. The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for novel ...
-
Alertgy Awarded Patent US20200217809A1 Apparatus For In Vivo Dielectric Spectroscopy
Alertgy has been granted a patent for their innovative and groundbreaking radio frequency sensor technology. The awarded patent, Apparatus for in vivo dielectric spectroscopy (US20200217809A1), focuses on sensor technology that is 100% non-invasive and continuously monitors blood glucose in a way that does not involve blood oxidase, but rather dielectric spectroscopy and radio frequency. As a ...
By Alertgy
-
Alertgy Welcomes Executive-Level Director of Engineering
Alertgy, the biotech startup that’s in the race to be the first company to develop an entirely non-invasive glucose monitoring system is proud to welcome a new hire in the Engineering Department: Benjamin Freer joins Alertgy as Director of Engineering/Principal Sensor Engineer. “By far, the most exciting aspect of being on the Alertgy team is the opportunity to see a dream of mine ...
By Alertgy
-
What’s Next For The Biotech Startup Alertgy and Their Non-Invasive Glucometer
Alertgy has nearly completed the process of miniaturizing its first generation NICGM® (Non-Invasive Continuous Glucose Monitor) into a smaller form factor that will be the size of modern smart watches. By replacing commercial off-the-shelf components with custom built parts, Alertgy has been able to greatly reduce the size of its NICGM. Throughout the design process, Alertgy has aimed to ...
By Alertgy
-
Alertgy Expands Into New Facility After Successful FlexTech Developer Partnership
Alertgy is excited to announce that we have moved to a new facility! We are still in the process of organizing our new headquarters, but we wanted to share with you our newly expanded capabilities and our progress thus far. Alertgy is also pleased to announce that it has been awarded a Developers Agreement between Alertgy Inc. and SEMI – Flextech. SEMI is the global industry association ...
By Alertgy
-
Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
By Bayer AG
-
LifeScan’s Response to the Invasion of Ukraine
For over 40 years, LifeScan’s vision has been to create a world without limits for people with diabetes and related conditions, and this remains as strong today as ever, and perhaps when our support is needed most. Therefore, we are responding to the urgent humanitarian need for diabetes health medical supplies resulting from the invasion of Ukraine. As part of our longstanding commitment ...
By LifeScan
-
World Diabetes Day
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
-
New and Encouraging Global Diabetes Market Research Shows People with Diabetes are More Motivated to Manage their Condition than Healthcare Providers May Realize
Key Research Survey Findings: 52 percent of healthcare providers agreed motivation is a major barrier to patients adhering to blood glucose monitoring compared to only 10 percent of people with diabetes who agreed motivation is a major barrier. Healthcare providers claimed they are recommending blood glucose management apps to only 25 percent of their patients, while 55% of patients who ...
By LifeScan
-
Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As communicated on 23 September 2021, ...
-
Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by baseline HbA1c, HbA1c variability, and diabetes duration in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) An exploratory ...
By Bayer AG
-
LifeScan Names Rekha Ramesh Chief Digital and Information Officer
LifeScan, a world leader in blood glucose monitoring and maker of the iconic OneTouch® brand, today announced that it has named Rekha Ramesh Chief Digital and Information Officer effective immediately. Rekha joins LifeScan with over 25 years of IT and digital strategy leadership experience and a proven track record driving customer-centric digital transformations that accelerate and maximize ...
By LifeScan
-
Longenesis and Medtronic Study Finds Insulin Pumps Contribute to Better Quality of Life for Type 1 Diabetes Patients
Longenesis announced today the preliminary results from its study on Type 1 Diabetes care in partnership with Medtronic. In less than three months, more than 85 patients participated in the research study, providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin injections. The study sponsors used participant data to ...
By Longenesis
-
Diamyd Medical joins international consortium in Type 1 Diabetes
Diamyd Medical will be a full voting member of the Type 1 Diabetes Consortium (T1DC) led by the US non-profit organization the Critical Path Institute (C-Path). The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development ...
-
Study Results Published in Diabetes Technology and Therapeutics Show Clinically Significant Improved Glycemic Control in People with Diabetes Using a Smart Blood Glucose Meter and Mobile App
LifeScan, a world leader in blood glucose monitoring, today announced that the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) has published Real World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth® connected Blood Glucose Meter with Mobile Diabetes Management Application, describing results from a retrospective analysis of real-world data ...
By LifeScan
-
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific ...
-
Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show that INV-202, the company’s lead peripheral CB1 ...
-
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the “Disease models and Clinical Applications: ...
-
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study First patient achieved insulin independence at Day 270; positive data in second patient; third patient has received full target dose with initiation of Part B VX-880 generally well tolerated in all three patients dosed to date ...
-
AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes
AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) will allow the company to pursue additional research in the use ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you